Key terms
About SLRX
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. Its pipeline includes SP-3164, a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. The company was founded in February 2014 and is headquartered in Houston, TX.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest SLRX news
Mar 28
10:59am ET
Biotech Alert: Searches spiking for these stocks today
Mar 27
10:47am ET
Biotech Alert: Searches spiking for these stocks today
Feb 23
6:13am ET
Salarius Pharmaceuticals Announces Executive Restructuring and Cost-Saving Measures
Feb 22
8:04am ET
Salarius announces additional cost saving measures, CEO transitions to part-time
Jan 03
8:39am ET
Salarius announces Phase 1/2 trial of seclidemstat resumes patient enrollment
No recent press releases are available for SLRX
SLRX Financials
Key terms
Ad Feedback
SLRX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
SLRX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range